Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
  • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
  • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
  • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
  • C07K16/46—Hybrid immunoglobulins
  • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
  • C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K2317/00—Immunoglobulins specific features
  • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
  • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K2319/00—Fusion polypeptide
  • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
  • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K2319/00—Fusion polypeptide
  • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K2319/00—Fusion polypeptide
  • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin

Definitions

• the present invention relates generally to the combination of recombinant DNA and monoclonal antibody technologies for developing novel therapeutic and other agents and, more particularly, to the production of chimeric antibodies specific for the human interleukin-2 receptor and the use of such chimeric antibodies in treating T-cell mediated human disorders.
• the immune response is mediated by two types of cells that interact specifically with foreign material, i.e. , antigens.
• B-cells are responsible for the production of antibodies.
• T-cells include a wide variety of cellular subsets controlling the in vivo function of both B-cells and a wide variety of other hematopoietic cells, including T- cells.
• IL-2 interleukin-2
• T-cell growth factor T-cell growth factor 2
• IL-2 interacts with a specific high-affinity membrane receptor (Greene, . , et al., Progress in Hematology XIV, E. Brown, ed. , Grune and Statton, New York (1986), at pgs. 283 ff) .
• the human IL-2 receptor is a complex glycoprotein, with one chain 55kD in size (Leonard, . et al., J. Biol. Che . 260;1872 (1985)).
• a gene encoding this protein has been isolated, and predicts a 272 a ino acid peptide, including a 21 amino acid signal peptide, (see, Leonard, . et al., Nature 311: 626 (1984)).
• IL-2 receptors can be detected on T-cells, but also on cells of the onocyte-macrophage family, Kupffer cells of the liver, Langerhans 1 cells of the skin and, of course, activated T-cells.
• resting T-cells, B-cells or circulating machrophages typically do not display the IL-2 receptor (Herrmann, et al., J. Exp. Med. 162:1111 (1985)).
• the anti-Tac monoclonal antibody has also been used to define lymphocyte functions that require IL-2 interaction, and has been shown to inhibit various T-cell functions, including the generation of cytotoxic and suppressor T lymphocytes in cell culture. Also, based on studies with anti-Tac, a variety of disorders are now associated with improper IL-2 receptor expression by T-cells, in particular adult T-cell leukemia.
• the IL-2 receptor has been shown to be an ideal target for novel therapeutic approaches to T-cell mediated diseases.
• the anti-Tac monoclonal antibody can be used either alone or as an immunoconjugate (e.g. with Ricin A, isotopes and the like) to effectively remove cells bearing the IL-2 receptor.
• These agents can, for example, theoretically eliminate IL-2 receptor-expressing leukemic cells, certain B-cells, or activated T-cells involved in a disease state, yet allow the retention of mature normal T- cells and their precursors to ensure the capability of mounting a normal T-cell immune response as needed.
• other T-cell specific agents can destroy essentially all peripheral T-cells, which limits therapeutic efficacy.
• the use of monoclonal antibodies specific for the IL-2 receptor can be expected to have therapeutic utility in autoimmune diseases, organ transplantation and any unwanted response by activated T-cells. Indeed, clinical trials have been initiated (see, generally, Waldman, T., Science 232:727- 732 (1986) , which is incorporated herein by reference) .
• the use of the anti-Tac monoclonal antibody has certain drawbacks, particularly in repeated therapeutic regimens. As a mouse monoclonal, it does not fix human complement well, whereas a human equivalent may be more efficient. More importantly, however, anti-Tac monoclonal antibody contains substantial urine amino acid sequences that will be antigenic when injected into a human patient.
• the present invention provides novel compositions useful in the treatment of T-cell mediated human disorders, the compositions containing a chimeric antibody specifically capable of binding to human IL-2 receptors, such as at the epitope bound by the anti-Tac monoclonal antibody.
• the IL-2 chimeric antibody can have two pairs of light chain/heavy chain complexes, wherein at least one pair has chains comprising mouse variable regions joined with human constant region segments, with or without naturally-associated J and D segments.
• the chimeric antibodies, or binding fragments thereof, of the present invention may be produced by a variety of recombinant DNA techniques, with ultimate expression in transfected cells, preferably immortalized eukaryotic cells, such as myeloma or hybridoma cells.
• Polynucleotides comprising a first sequence coding for a human immunoglobulin constant region and a second sequence coding for the desired mouse immunoglobulin variable or hypervariable region can be produced synthetically or by combining appropriate cDNA and genomic DNA segments.
• the compounds When the chimeric antibodies are complexed with a cytotoxic agent, such as a radionuclide, a ribosomal inhibiting protein or a cytotoxic agent active at cell surfaces, the compounds will be particularly useful in treating T-cell mediated disorders.
• a cytotoxic agent such as a radionuclide, a ribosomal inhibiting protein or a cytotoxic agent active at cell surfaces
• these compounds can be provided in a pharmaceutically accepted dosage form, which will vary depending on the mode of administration.
• Figure 1 depicts the DNA coding sequence and putative amino acid sequence of the V and J regions of the anti-Tac light chain.
• Figure 2 depicts the DNA coding sequence and putative amino acid sequence of the V and J regions of the anti-Tac heavy chain.
• Figures 3-10 are schematic diagrams of the plasmids utilized to demonstrate the present invention.
• Figure 11 represents an overview of a preferred strategy for preparation of V and J regions for insertion into plasmids.
• DNA sequences encoding mouse variable/human constant region chimeric antibodies capable of binding epitopes on human IL-2 receptors are provided.
• large quantities of chimeric antibodies can be produced.
• the chimeric antibodies will have substantially the same binding profile or characteristics as (e.g. , be cross-reactive or capable of blocking) the binding of the anti-Tac monoclonal antibody, such as antibodies produced by the myeloma cell line deposited with the A.T.C.C. and designated accession number CRL 9688.
• These chimeric antibodies find use, for example, in the treatment of T-cell mediated disorders in human patients.
• the basic immunoglobin structural unit is known to comprise a tetramer.
• Each tetramer is composed of two identical pairs of polypeptide chains, each pair having one "light" (about 25kD) and one "heavy" chain (about 50-70kD) .
• the NH -terminus of each chain begins a variable region of about 100 to 110 or more amino acids primarily responsible for antigen recognition.
• the COOH terminus of each chain defines a constant region primarily responsible for effector function.
• Light chains are classified as either kappa or lambda.
• Heavy chains are classified (and subclassified) as gamma, mu, alpha, delta, or epsilon, and define the immunoglobulin's isotype as IgG, IgM, IgA, IgD and IgE, respectively.
• the variable and constant regions are joined by a "J" region of about 12 or more amino acids, with the heavy chain also including a "D” region of about 12 more amino acids.
• Chimeric antibodies are antibodies whose light and heavy chain genes have been constructed, typically by genetic engineering, from immunoglobulin gene segments belonging to different species.
• the variable (V) segments of the genes for a mouse monoclonal antibody may be joined to human constant (C) segments, such as 7 , and 7 .
• a preferred therapeutic chimeric antibody is thus a hybrid protein consisting of the V or antigen-binding domain from a mouse antibody and the C or effector domain from a human antibody, although other mammalian species may be used.
• Human chimeric antibodies have at least three potential advantages over mouse antibodies for use in human therapy: 1) Because the effector portion is human, it may interact better with the other parts of the human immune system (e.g. , destroy the target cells more efficiently by complement-dependent cytotoxicity (CDC) or antibody-dependent cellular cytotoxicity (ADCC) ) .
• CDC complement-dependent cytotoxicity
• ADCC antibody-dependent cellular cytotoxicity
• the human immune system should not recognize the C region of the chimeric antibody as foreign, and therefore the antibody response against an injected chimeric antibody should be less than against a totally foreign mouse antibody.
• Injected mouse antibodies have been reported to have a half-life in the human circulation much shorter than the half-life of normal antibodies (Shaw, D. et al., J. Immunol. 138:4534-4538 (1987)) . It is possible that injected chimeric antibodies will have a half-life more like that of human antibodies, allowing smaller and less frequent doses to be given.
• the present invention is directed to recombinant DNA segments encoding the heavy and/or light chain variable or hypervariable regions from the anti-Tac monoclonal antibody.
• the DNA segments encoding these regions will typically be joined to DNA segments encoding appropriate constant regions, such as human gamma heavy chain regions or human kappa light chain regions.
• appropriate constant regions such as human gamma heavy chain regions or human kappa light chain regions.
• the preferred variable region DNA sequences which on expression code for the polypeptide chains comprising the anti-Tac light and heavy chain variable regions (with naturally-associated J regions) , are shown in Figures 1 and 2, respectively. Due to codon degeneracy and non-critical amino-acid substitutions, other DNA sequences can be readily substituted for those sequences, as detailed below.
• the DNA segments will typically further include an expression control DNA sequence operably linked to the chimeric antibody coding sequences, including naturally- associated or heterologous promoter regions.
• the expression control sequences will be eukaryotic promoter systems in vectors capable of transforming or transfecting eukaryotic host cells. Once the vector has been incorporated into the appropriate host, the host is maintained under conditions suitable for high level expression of the nucleotide sequences, and, as desired, the collection and purification of the light chains, heavy chains, light/heavy chain dimers or intact chimeric antibodies may follow.
• variable and constant regions are subject to substantial natural modification, yet are “substantially identical” and still capable of retaining their respective activities.
• Human constant region DNA sequences can be isolated in accordance with well known procedures from a variety of human cells, but preferably immortalized B-cells. Suitable source cells for the DNA sequences and host cells for expression and secretion can be obtained from a number of sources, such as the American Type Culture Collection ("Catalogue of Cell Lines and Hybridomas," Fifth edition (1985) Rockville, Maryland, U.S.A., which is incorporated herein by reference).
• substantially identical modified heavy and light chains can be readily designed and manufactured utilizing various recombinant DNA techniques well known to those skilled in the art.
• the chains can vary from the naturally-occurring sequence at the primary structure level by several amino acid substitutions, terminal and intermediate additions and deletions, and the like.
• polypeptide fragments comprising only a portion (usually at least about 60-80%, typically 90-95%) of the primary structure may be produced, which fragments possess one or more immunoglobulin activities (e.g.. complement fixation activity) , while exhibiting lower immunogenicity.
• the immunoglobulin-related genes contain separate functional regions, each having one or more distinct biological activities. These may be fused to functional regions from other genes (e.g. r enzymes, see, commonly assigned U.S.S.N. 132,387, filed Dec. 15, 1987, which is incorporated herein by reference) to produce fusion proteins (e.g.. immunotoxins) having novel properties.
• r enzymes see, commonly assigned U.S.S.N. 132,387, filed Dec. 15, 1987, which is incorporated herein by reference
• modifications of the genes may be readily accomplished by a variety of well-known techniques, such as site-directed mutagenesis (see. Gillman and Smith, Gene 8.:81-97 (1979) ; Roberts, S. et al. Nature 328:731-734 (1987); and U.S. Patent no.
• Preferred DNA segments encoding variable regions of the present invention will typically be substantially homologous to the sequences of Figures 1 and 2 (i.e., capable of hybridizing to the sequences under stringent conditions of low salt and high temperature) , most preferrably at least about 90-95% homologous or more.
• nucleic acid sequences of the present invention capable of ultimately expressing the desired chimeric antibodies can be formed from a variety of different polynucleotides (genomic or cDNA, RNA, etc.) and components (e.g. , V, J, D, and C regions) , as well as by a variety of different techniques. Joining appropriate genomic sequences is presently the most common method of production, but cDNA sequences may also be utilized (see, European Patent Application Nos. 85102655.8, 85305604.2, 84302368.0 and 85115311.4, as well as PCT Application Nos. GB85/00392 and US86/02269, all of which are incorporated herein by reference) .
• the DNA sequences of the present invention will be expressed in hosts after the sequences have been operably linked to (i.e. , positioned to ensure the functioning of) an expression control sequence.
• These expression vectors are typically replicable in the host organisms either as episomes or as an integral part of the host chromosomal DNA.
• expression vectors will contain selection markers, e.g. , tetracycline or neomycin, to permit detection of those cells transformed with the desired DNA sequences (see, e.g. , U.S. Patent 4,704,362, which is incorporated herein by reference) .
• E. coli is one prokaryotic host useful particularly for cloning the DNA sequences of the present invention.
• microbial hosts suitable for use include bacilli, such as Bacillus subtilus, and other enterobacteriaceae, such as Salmonella, Serratia, and various Pseudomonas species.
• prokaryotic hosts one can also make expression vectors, which will typically contain expression control sequences compatible with the host cell (e.g. , an origin of replication) .
• expression control sequences compatible with the host cell (e.g. , an origin of replication) .
• any number of a variety of well- known promoters will be present, such as the lactose promoter system, a tryptophan (trp) promoter system, a beta-lactamase promoter system, or a promoter system from phage lambda.
• the promoters will typically control expression, optionally with an operator sequence, and have ribosome binding site sequences and the like, for initiating and completing transcription and translation.
• Saccharomvces is a preferred host, with suitable vectors having expression control sequences, such as promoters, including 3-phosphoglycerate kinase or other glycolytic enzymes, and an origin of replication, termination sequences and the like as desired.
• mammalian tissue cell culture may also be used to produce the polypeptides of the present invention (see, Winnacker, "From Genes to Clones,” VCH Publishers, N.Y., N.Y. (1987), which is incorporated herein by reference) .
• Eukaryotic cells are actually preferred, because a number of suitable host cell lines capable of secreting intact immunoglobulins have been developed in the art, and include the CHO cell lines, various COS cell lines, HeLa cells, myeloma cell lines, etc, but preferably transformed B-cells or hybrido as.
• Expression vectors for these cells can include expression control sequences, such as an origin of replication, a promoter, an enhancer (Queen, C.
• Preferred expression control sequences are promoters derived from immunoglobulin genes, SV40, Adenovirus, Bovine Papilloma Virus, and the like.
• the vectors containing the DNA segments of interest can be transferred into the host cell by well-known methods, which vary depending on the type of cellular host. For example, calcium chloride transfection is commonly utilized for prokaryotic cells, whereas calcium phosphate treatment may be used for other cellular hosts. (See generally, Maniatis et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Press, (1982), which is incorporated herein by reference.)
• the whole chimeric antibodies, their dimers, or individual light and heavy chains of the present invention can be purified according to standard procedures of the art, including ammonium sulfate precipitation, fraction column chro atography, gel electrophoresis and the like. (See, generally. Scopes, R. , Protein Purification, Springer-Verlag, N.Y. (1982).) Once purified, partially or to homogeneity as desired, the polypeptides may then be used therapeutically or in developing and performing assay procedures, immunofluorescent stainings, and the like. (See, generally, Immunological Methods, Vols. I and II, Eds. Lefkovits and Pernis, Academic Press, New York, N.Y. (1979 and 1981).)
• the chimeric antibodies of the present invention will typically find use individually in treating a T-cell mediated disease state. Generally, where the cell linked to a disease has been identified as IL-2 receptor bearing, then the chimeric antibodies are suitable (see, U.S.S.N. 7- 085,707, entitled “Treating Human Malignancies and Disorders,” which is incorporated herein by reference) .
• Other diseases include Type I diabetes, multiple sclerosis, rheumatoid arthritis, Lupus erythematosus, and Myasthenia Gravis.
• the antibodies of the present invention may also be used in combination with other antibodies, particularly human chimeric antibodies or human monoclonal antibodies reactive with other markers on cells responsible for the disease.
• suitable T-cell markers can include those grouped into the so-called "Clusters of Differentia ion," as named by the First International Leukocyte Differentiation Workshop, Leukocyte Typing, Eds. Bernard, et al., Springer-Verlag, N.Y. (1984) , which is incorporated herein by reference.
• the chimeric antibodies can also be used as separately administered compositions given in conjunction with chemotherapeutic or immunosuppressive agents.
• the agents will include a cephalosporin or a purine analog (e.g. , methotrexate, 6-mercaptopurine, or the like) , but numerous additional agents (e.g.. cyclophospha ide, sulfa drugs, etc.) well-known to those skilled in the art may also be utilized.
• a preferred pharmaceutical composition of the present invention comprises the use of the subject chimeric antibodies in immunotoxins.
• I munotoxins are characterized by two components and are particularly useful for killing selected cells in vitro or in vivo.
• One component is a cytotoxic agent which is usually fatal to a cell when attached or absorbed.
• the second component known as the "delivery vehicle,” provides a means for delivering the toxic agent to a particular cell type, such as cells comprising a carcinoma.
• the two components are commonly chemically bonded together by any of a variety of well-known chemical procedures.
• the cytotoxic agent is a protein and the second component is an intact immunoglobulin, such as a chimeric antibody
• the linkage may be by way of heterobifunctional cross-linkers, e.g..
• Cytotoxic agents can include radionuclides, such as Iodine-131, Yttrium-90, Rhenium-188, and Bismuth-212; a number of chemotherapeutic drugs, such as vindesine, methotrexate, adriamycin, and cisplatinum; and cytotoxic proteins such as ribosomal inhibiting proteins, pokeweed antiviral protein, abrin and ricin (or their A- chains, diphtheria toxin A-chains, Pseudomonas exotoxin A, etc.) or an agent active at the cell surface, such as the phospholipase enzymes (e.g. , phospholipase C) .
• radionuclides such as Iodine-131, Yttrium-90, Rhenium-188, and Bismuth-212
• chemotherapeutic drugs such as vindesine, methotrexate, adriamycin, and cisp
• the delivery component of the immunotoxin will include the chimeric antibodies of the present invention. Intact chimeric immunoglobulins or their binding fragments, such as Fab, F(ab 2 ) , etc., are preferably used. Typically, the chimeric antibodies in the immunotoxins will be of the human IgM or IgG isotype, but other mammalian constant regions may be utilized as desired.
• compositions for parenteral administration are particularly - useful for parenteral administration, i.e. , subcutaneously, intramuscularly or intravenously.
• the compositions for parenteral administration will commonly comprise a solution of the antibody or a cocktail thereof dissolved in an accept- able carrier, preferably an aqueous carrier.
• aqueous carriers can be used, e.g. , water, buffered water, 0.4% saline, 0.3% glycine and the like. These solutions are sterile and generally free of particulate matter.
• These compositions may be sterilized by conventional, well known sterilization techniques.
• compositions may contain pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions such as pH adjusting and buffering agents, toxicity adjusting agents and the like, for example sodium acetate, sodium chloride, potassium chloride, calcium chloride, sodium lactate, etc.
• concentration of antibody in these formulations can vary widely, i.e.. from less than about 0.5%, usually at or at least about 1% to as much as 15 or 20% by weight and will be selected primarily based on fluid volumes, viscosities, etc., in accordance with the particular mode of administration selected.
• a typical pharmaceutical composition for intramuscular injection could be made up to contain 1 ml sterile buffered water, and 50 g of antibody.
• a typical composition for intravenous infusion could be made up to contain 250 ml of sterile Ringer's solution, and 150 mg of antibody.
• Actual methods for preparing parenterally administrable compositions will be known or apparent to those skilled in the art and are described in more detail in, for example, Remington's Pharmaceutical Science, 15th Ed. , Mack Publishing Company, Easton, Pennsylvania (1980) , which is incorporated herein by reference.
• the antibodies of this -invention can be ly ⁇ philized for storage and reconstituted in a suitable carrier prior to use. This technique has been shown to be effective with conventional immune globulins and art-known lyophilization and reconstitution techniques can be employed. It will be appreciated by those skilled in the art that lyophilization and reconstitution can lead to varying degrees of antibody activity loss (e.g. , with conventional immune globulins, IgM antibodies tend to have greater activity loss than IgG antibodies) and that use levels may have to be adjusted to compensate.
• compositions containing the present human chimeric antibodies or a cocktail thereof can be administered for the prophylactic and/or therapeutic treatments.
• compositions are administered to a patient already, in an amount sufficient to cure or at least partially arrest the infection and its complications.
• An amount adequate to accomplish this is defined as a "therapeutically effective dose.” Amounts effective for this use will depend upon the severity of the infection and the general state of the patient's own immune system, but generally range from about 1 to about 200 mg of antibody per dose, with dosages of from 5 to 25 mg per patient being more commonly used. It must be kept in mind that the materials of this invention may generally be employed in serious disease states, that is life-threatening or potentially life- threatening situations.
• compositions containing the present antibodies or a cocktail thereof are administered to a patient not already in a disease state to enhance the patient's resistance.
• Such an amount is defined to be a "prophylactically effective dose.”
• the precise amounts again depend upon the patient's state of health and general level of immunity, but generally range from 0.1 to 25 mg per dose, especially 0.5 to 2.5 mg per patient.
• Single or multiple administrations of the compositions can be carried out with dose levels and pattern being selected by the treating physician.
• the pharmaceutical formulations should provide a quantity of the antibody(ies) of this invention sufficient to effectively treat the patient.
• Chimeric antibodies of the present invention can further find a wide variety of utilities vitro.
• the chimeric antibodies can be utilized for T-cell typing, for isolating specific IL-2 receptor bearing cells or fragments of the receptor, for vaccine preparation, or the like.
• the chimeric antibodies may either be labeled or unlabeled.
• Unlabeled antibodies can be used in combination with other labeled antibodies (second antibodies) that are reactive with the chimeric antibody, such as antibodies specific for human immunoglobulin constant regions.
• second antibodies labeled antibodies
• the chimeric antibodies can be directly labeled.
• labels may be employed, such as radionuclides, fluorescers, enzymes, enzyme substrates, enzyme cofactors, enzyme inhibitors, ligands
• Kits can also be supplied for use with the subject antibodies in the protection against or detection of a cellular activity or for the presence of a selected antigen.
• the subject antibody composition of the present invention may be provided, usually in a lyophilized form in a container, either alone or in conjunction with additional antibodies specific for the desired cell type.
• the antibodies which may be conjugated to a label or toxin, or unconjugated, are included in the kits with buffers, such as Tris, phosphate, carbonate, etc., stabilizers, biocides, inert proteins, e.g.
• serum albumin or the like, and a set of instructions for use.
• these materials will be present in less than about 5% wt. based on the amount of active antibody, and usually present in total amount of at least about 0.001% wt. based again on the antibody concentration.
• a second antibody capable of binding to the chimeric antibody is employed in an assay, this will usually be present in a separate vial.
• the second antibody is typically conjugated to a label and formulated in an analogous manner with the antibody formulations described above.
• a splice and polyadenylation signal from the animal virus SV40 (850 bp) .
• e Another part of SV40 containing its origin of replication (700 bp) ;
• f Part of the plasmid pBR322, extending from the Sph I site to the Eco Rl site of the plasmid pMLl (Lusky, M and Botchan, M. Nature 293:79-81: 2300 bp) including the Amp gene and origin of replication.
• pKcatH was cut with Bgl II, and the ends filled in with Klenow polymerase.
• An Xba I linker having the sequence GCTCTAGAGC, was inserted at the filled-in Bgl II site. The resulting plasmid is called pKcatH - Xba.
• pKcatH - Xba was cut partially with Xho II, run on an agar ⁇ se gel, and full-length linear plasmid (i.e. , plasmid cut exactly once with Xho II) was isolated.
• the DNA was cut with Bam HI, run on a gel and the 5600 bp fragment isolated. Because of its size, this fragment had to extend from the Bam site to the Xho II site at the end of the CAT gene (Fig. 3). The fragment was ligated by itself.
• the resulting plasmid is called pKcatH - Xba - BX. It is similar to pKcatH but has an Xba I site in place of the Bgl II site and is missing the Xho II - Bam HI SV40 fragment (Fig. 4) .
• the plasmid pSV2neo (Southern, P.J. and Berg, P. J. Mol. App. Genet. 1:327-341 (1982)), was cut with Eco RI and Bam HI, and the large Eco RI - Bam HI fragment ligated to the same Eco RI - Bam HI fragment from pKcatH - Xba - BX used in (4) .
• the resulting plasmid is called pSV2neo - EH - K , which is like pSV2gpt - EH - K, but has the Neo gene in place of the Gpt gene.
• pSV2gpt - E réelle - c was cut with Xba I and Bam HI and the ends filled in with Klenow polymerase.
• a fragment of the cloned human K constant segment gene (Hieter, P.A. et al., Cell 22:197-207 (1980)) was purified, extending from a Hind III site 336 bp before the coding region, to an Xba I site about 800 bp beyond the coding region, and the ends filled in.
• the two fragments were ligated together, and a plasmid selected in which the Hind III site of the second*fragment was joined to the Xba I site and the Xba I site of the second fragment to the Bam HI site.
• pV ⁇ l Fig. 6
• An Xba I fragment containing the VJ region of the cloned anti-Tac light chain gene was prepared by in vitro mutagenesis (see, below) .
• pV ⁇ l was cut with Xba I, treated with phosphatase, and ligated with the Xba I fragment.
• a plasmid was selected in which the VJ region had the same orientation as the following C region, and called pLTAC2 (Fig. 7) .
• pSV2neo - E réelle - K was cut with Xba I and Bam HI and the ends filled in with Klenow polymerase.
• a 2800 bp fragment containing the human C7I gene was purified from the phage HG3A (Ellison, J.W. et al., Nucleic Acids Res. 10:4071-4079 (1982)), extending from a Hind III site 210 bp before the CHI exon to a Pvu II site about 1100 bp after the CH3 exon, and the ends filled in.
• the two fragments were ligated together, and a plasmid selected in which the Hind III site of the second fragment was joined to the Xba I site and the Pvu II site of the second fragment to the Bam HI site. Because of the sequences of these sites, this recreated an Xba I site and a Bam HI site.
• the new plasmid is called pV 7 lneo (Fig. 8) .
• pSV2neo - E réelle - K was cut with Xba I and Bam HI and the ends filled in with Klenow polymerase.
• a 3600 bp fragment containing the human C 7 3 gene (Takahashi, N. et al., Cell ⁇ 671-679 (1982)) was purified extending from a Hind III site 210 bp before the CHI exon to a Pvu II site about 1100 bp after the CH3 exon, and the ends filled in.
• the two fragments were ligated together, and a plasmid selected in which the Hind III site of the second fragment was joined to the Xba I site and the Pvu II site of the second fragment to the Bam HI site.
• the new plasmid is called pV 3neo and is identical to pV7lneo except it has the C 7 3 gene instead of C 7 I. 10.
• An Xba I fragment containing the VJ region of the cloned anti-Tac heavy china gene was prepared by in vitro mutagenesis (see, below) .
• pV7lneo was cut with Xba I, treated with phosphatase, and ligated with the Xba I fragment.
• a plasmid was selected in which the VJ region had the same orientation as the following C region, and called pHTAC.
• PV7I Three additional plasmids were prepared respectively from pV7lneo, pV 3neo and pHTAC, called respectively PV7I, PV73 and pGTACl.
• the original plasmid was cut with Hind III and Bam HI, and the large Hind III - Bam HI fragment purified.
• the plasmid pXBohph containing the Hyg gene (Blochlinger, K. and Diggelmann, H. Mol. Cell. Biol. 4:2929-2931 (1984)) was cut with Hind III and Bam HI and a 1600 bp fragment containing the Hyg gene purified.
• the fragments from the original plasmids were each ligated to the pXbohph fragment.
• PV 7 I is shown in Fig. 9 and pGTACl in Fig.
• pHTAC was cut with Xba I and the small Xba I fragment, containing the heavy VJ region, purified.
• PV 3 was cut with Xba I, treated with phosphatase, and ligated with the small Xba I fragment.
• a plasmid was selected in which the VJ region had the same orientation as the following C region, and called pGTAC3. It is similar to pGTACl, but has the C 7 3 region instead of the C7I region.
• mRNA was extracted from approximately 10-8 ascites cells of the anti-Tac hybrido a by the guanidium isothiocyanate method followed with poly A selection on Hybond- AP paper (Amersham) .
• cDNA was prepared by the method of Gubler and Hoffman (Gubler, U. and Hoffman, B.J. Gene
• plaques Approximately 10,000 plaques were screened with the oligonucleotide probes. About 100 plaques were positive for the 7 probe and 40 for the 7 probe.
• VJ segments of the other pair of K clones were sequences completely and were identical (Fig. 1) .
• This light chain uses the JK5 segment and contains all the amino acid residues conserved in mouse K light chains (Kabat, E. A. et al.. Sequences of Proteins of Immunological Interest, particularly pg. 45 et seq, all of which is incorporated herein by reference) .
• Plasmid vectors were prepared for the construction and expression of chimeric light and heavy chain genes as described above.
• the plasmid pV ⁇ l (Fig. 6) contains the human K genomic C segment, including 336 bp of the preceding intron and the poly A signal. It also contains a strong promoter sequence from the MOPC 41 K gene, and the heavy chain enhancer sequence. There is a unique Xba I site between the promoter and the C intron.
• the plasmid also contains the gpt gene for selection. Two other very similar plasmids were prepared by using the human 71 and 7 3 C regions in place of the K C region.
• the region inserted between the Xba I and Bam HI sites extended form about 210 bp 5* of the CHI exon to about 1100 bp 3 ' of the CH3 exon.
• the gpt gene was replaced with the hyg gene to confer resistance to hygromycin.
• the next 16 nucleotides were the same as the sequence that follows JK5 in mouse genomic DNA, and therefore included a splice donor signal.
• the final nucleotides of the oligo consisted of an Xba I site followed by a short irrelevant sequence.
• This oligonucleotide was hybridized to the Ml3 phage DNA containing the K CDNA and extended with Klenow polymerase (Fig. 3) .
• the DNA was denatured and hybridized to a "reverse primer," which represents M13 DNA 5' to the cDNA insert.
• the reverse primer was extended, and the DNA cut with Xba I.
• the Xba I fragment consisting of the extended VJ segment of the cDNA was purified, and cloned in the correction orientation into the Xba I site of pV ⁇ l to obtain the plasmid pLTAC2 (Fig. 7) .
• the final chimeric K gene has a VJ-C intron, of which the first 14 bp and last 209 bp are respectively the same as in mouse and human genomic DNA, as verified by direct sequencing of the construct.
• the gene is transcribed from a K promoter, stimulated by the heavy chain enhancer. Based on results obtained with deleted introns, we expected that the intron would be correctly spliced from the transcribed RNA.
• the VJ region from the anti-Tac 72a heavy chain cDNA, followed by a splice donor signal was inserted into the Xba I site of pV 7 lneo.
• the resulting plasmid pHTAC contains a chimeric heavy chain gene, with a synthetic intron between the mouse VJ and human C 7 I segments.
• RF DNA of the phage M13mpll was cut with Eco Rl and Xba I, the ends were filled-in, and the DNA ligated was ligated and transformed into JM101 cells. A plaque was picked and the DNA was sequenced to verify that the ends of the DNA had joined correctly, recreating the Eco Rl and Xba I sites with the intervening DNA segment deleted. This phage is designated M13mpllD. Eco Rl fragments containing the anti-Tac light and heavy chain cDNAs were separately cloned into the Eco Rl site of M13mpll, so that their 5' ends aubbed the Xba I site. The resulting phage are respectively denoted M13mpllL and M13mpllH.
• the following 48-nucleotide long primer was synthesized and gel-purified: CCAGAATTCTAGAAAAGTGTACTTACGTTTCAGCTCCAGCTTGGTCCC. From the 3' end, the first 22 residues of the primer are the same as the last 22 bp of the JK5 segment (non-coding strand) . The next 16 nucleotides are the same as the sequence that follows JK5 in mouse genomic DNA and therefore includes a splice donor signal (abbreviated SD in Fig. 11) . The final nucleotides of the oligo consist of an Xba I site followed by a short irrelevant sequence.
• Klenow polymerase The solution was incubated for 30 minutes at 37 X C. 50 ng of the "reverse primer" AACAGCTATGACCATG (New England Biolabs) , which can hybridize to the newly synthesized strand upstream of the Xba I site (Fig. 11) , was added. The solution was incubated at 95 ⁇ C for 3 min and put on ice. An additional 4 ul of 200 uM each dNTP and 5u Klenow polymerase was added, and the solution incubated for 30 minutes at 37 C. The solution was extracted with phenol- chloroform, precipitated with ethanol, resuspended, and digested with 20u Xba I.
• AACAGCTATGACCATG New England Biolabs
• the digested DNA was run on a 4% polyacrylamide gel and visualized with ethidiu bromide. In addition to high molecular weight DNA, an approximately 400 bp fragment was visible, corresponding to the VJ region of the light chain cDNA with a "tail" (Fig. 11) . The fragment was cloned directly into the Xba I site of pV ⁇ l in the correct orientation.
• the first 21 residues of the primer are the same as the last 21 bp of the JH2 segment (non-coding strand) .
• the next 19 nucleotides are the same as the sequence that follows JH2 in mouse genomic DNA and therefore includes a splice donor signal.
• the final nucleotides of the oligo consist of an Xba I site followed by a short irrelevant sequence.
• This primer was hybridized to M13mpllH DNA following the same protocol as above, in order to synthesize a fragment containing the VJ region of the heavy chain cDNA. The fragment was cloned directly into the Xba I site of pV 7 lneo in the correct orientation.
• Chimeric Antibody Specificity CR2-2 and CEM cells are human T cell lines that are respectively positive and negative for surface expression of the IL2 receptor (IL2R) .
• Whole CR2-2 cells were used to demonstrate binding specificity of the chimeric antibody in an ELISA assay, and CEM cells were used as a negative control.
• IL2R IL2 receptor
• Antibody to be tested was prepared in several ways.
• Anti-Tac monoclonal antibody supplied by T. Waldmann, was purified from mouse ascites by passage through a DEAE-dextran column.
• the cell line L40H4 created by transfecting SP2/0 cells with the chimeric light and gamma 1 heavy chain plasmids pLTAC2 and pGTACl (described above) , was injected into mice to form an ascites. From 3 mis of ascites fluid, 650 ⁇ g of chimeric gamma 1 antibody was purified by passage through a column of Baker Abx and a size exclusion column.
• 2 x 10 6 cells were mixed with either purified antibody in 20 ⁇ l FACS buffer or 20 ⁇ l media supernatent from the transfected cell lines, and incubated on i ce f or 2 hr. The cells were washed 3 times with 1 ⁇ l of FACS buffer (being collected by brief centrifugation after each wash) .
• the cells that had been incubated with anti-Tac antibody were mixed with 0.5 ⁇ l peroxidase-conjugated goat anti-mouse antibody (Fab) ' fragment (Tago Immunologicals, Burlingame, California) in 20 ⁇ l FACS buffer, and the cells that had been incubated with chimeric antibody were mixed with 0.5 ⁇ l peroxidase- conjugated goat anti-human gamma chain (Fab) ' fragment (Tago) in 20 ⁇ l FACS buffer.
• the cells were incubated for 30 min on ice and then washed 3 times with FACS buffer. They were then mixed with 100 ⁇ l peroxidase development solution and incubated for 5 min at room temperature.
• the cells were spun out and the supernatents were transferred to a 96-well plate and the OD's determined in an ELISA reader. The OD's at 414 nm for the cells treated with each antibody are given in Table l.
• the anti-Tac antibody itself bound to the IL2R+ CR2-2 cells but not to the IL2R- CEM cells.
• An equal amount of purified gamma 1 chimeric antibody gave an equivalent amount of binding to the CR2-2 cells as the anti- Tac, and also failed to bind to the CEM cells. All the supernatants from both the chimeric antibody producing cells bound to the CR2-2 cells. As additional negative controls, the 51.3 supernatant did not bind to the CEM cells, and supernatant from the parental SP2/0 cells did not bind the CR2-2 cells.
• the plate was washed, incubated with peroxidase-conjugated goat anti-human gamma chain antibody, washed again, incubated with peroxidase developing solution and the OD's at 414 nm determined in an ELISA reader.
• the media supernatants contained respectively about 8 and 7 ng per ⁇ l, that is the cells secreted 8 and 7 ⁇ g antibody per 10 6 cells per 24 hr.
• the mixed lymphocyte reaction is a model for transplant rejection and was used to analyze the effectiveness of the chimeric anti-Tac antibodies.
• Table 3 The experiments shown in Table 3 below were performed by standard methods (see, e.g. , Strong, D.M. et al., In Vitro Stimulation of Murine Spleen Cells Using a Microculture System and a .
• the chimeric antibodies of the present invention offer numerous advantages of other human IL-2 receptor-specific antibodies.
• the present human chimeric antibodies can be more economically produced and contain substantially less foreign amino acid sequences. This reduced likelihood of antigenicity after injection into a human patient represents a significant therapeutic improvement.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Immunology (AREA)
• Life Sciences & Earth Sciences (AREA)
• Organic Chemistry (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Animal Behavior & Ethology (AREA)
• Veterinary Medicine (AREA)
• Pharmacology & Pharmacy (AREA)
• Genetics & Genomics (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Engineering & Computer Science (AREA)
• General Chemical & Material Sciences (AREA)
• Biochemistry (AREA)
• Biophysics (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Molecular Biology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Microbiology (AREA)
• Mycology (AREA)
• Epidemiology (AREA)
• Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
• Preparation Of Compounds By Using Micro-Organisms (AREA)
• Peptides Or Proteins (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Micro-Organisms Or Cultivation Processes Thereof (AREA)

Applications Claiming Priority (2)

Publications (2)

Family

ID=22666118

Family Applications (1)

Country Status (6)

Families Citing this family (171)

Family Cites Families (6)

• 1989
  • 1989-04-13 KR KR1019890702368A patent/KR900700134A/ko not_active Withdrawn
  • 1989-04-13 JP JP1505043A patent/JPH02503867A/ja active Pending
  • 1989-04-13 FI FI895955A patent/FI895955A7/fi not_active Application Discontinuation
  • 1989-04-13 AU AU35445/89A patent/AU631545B2/en not_active Ceased
  • 1989-04-13 EP EP19890905832 patent/EP0362371A4/en not_active Withdrawn
  • 1989-04-13 WO PCT/US1989/001578 patent/WO1989009622A1/en not_active Ceased

Also Published As

Similar Documents

Legal Events